Millennium Management
ADXN

Millennium Management’s Addex Therapeutics ADXN Stock Holding History

Millennium Management’s Portfolio ADXN Stock Details ADXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-998
Closed -$16K – 6529
2022
Q3 		$16K Buy
+998
New +$22.3K ﹤0.01% 6517

Other funds holding ADXN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Millennium Management's ADXN Position: Q4 2022 in Review

Millennium Management sold out of Addex Therapeutics (ADXN) in Q4 2022, closing a stake of 998 shares — an estimated $16K sold.

Millennium Management first reported a position in ADXN in Q3 2022 and held it in 1 quarter. The position peaked at $16K in Q3 2022. 8 funds tracked by Wall St. Rank hold ADXN as of Q4 2022.

  • Millennium Management reported no remaining Addex Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Millennium Management sold 998 Addex Therapeutics shares in Q4 2022, an estimated $16K.
  • Millennium Management first reported a position in Addex Therapeutics in Q3 2022 and held it in 1 quarter.
  • Millennium Management's Addex Therapeutics position peaked at $16K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Addex Therapeutics as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.